Key result
Rivaroxaban use in nonvalvular atrial fibrillation has expanded from high-risk elderly patients to the broader population, with overall stroke/TIA and major bleeding rates of 2.3 and 4.2 per 100 patient-years.
Why the study?
Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed over time?
Observational
Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed over time?
The use of rivaroxaban in nonvalvular atrial fibrillation has expanded from initially targeting very elderly patients with high bleeding risk to the broader patient population.
Later rivaroxaban prescriptions targeted older NVAF patients with higher bleeding risk; leaves open whether this reflects evolving real-world adoption.
AIM: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban. METHODS: Retrospective study in which patients treated with rivaroxaban were divided into two groups according to the data in which the initial prescription was performed (November 2012-December 2013 and January 2014-January 2017). RESULTS: -VASc 3.8 ± 1.5; HAS-BLED 2.0 ± 0.8.) were included. Age and bleeding risk were higher in those subjects in which the prescription started earlier. Rates of stroke/TIA, major bleeding and intracranial hemorrhage were 2.3/4.2/0.6 events/100 patient-years, respectively. CONCLUSION: Although, the initial prescription of rivaroxaban was mainly performed in very elderly patients and/or with a higher bleeding risk, this has been extended to the overall nonvalvular atrial fibrillation population.
No takes yet. Share an insight, caveat, or question.
Quezada et al. (2018) conducted an observational in Nonvalvular atrial fibrillation. Rivaroxaban vs. Earlier vs later prescription periods was evaluated on Rates of stroke/TIA, major bleeding and intracranial hemorrhage. Rivaroxaban use in nonvalvular atrial fibrillation has expanded from high-risk elderly patients to the broader population, with overall stroke/TIA and major bleeding rates of 2.3 and 4.2 per 100 patient-years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: